Page 323

90. Rudick R, Antel J, Confavreux C, et al. 1997. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol.; 42: 379-82.

91. Schwartz CE, Vollmer T, Lee H. 1999. Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Neurology.; 52: 63-70.

92. Scolding NJ, Franklin RJ. 1997. Remyelination in demyelinating disease. Baillieres Clin Neurol.; 6: 525-48.

93. Serreze DV, Leiter EH, Worthen SM, Shultz LD. 1988. NOD marrow stem cells adoptively transfer diabetes to resistant (NOD x NON)F1 mice. Diabetes.; 37: 252-5.

94. Snyder EY, Macklis JD. 1995-1996. Multipotent neural progenitor or stem-like cells may be uniquely suited for therapy for some neurodegenerative conditions. Clin Neurosci.; 3: 310-6.

95. Stangel M, Boegner F, Klatt CH, Hofmeister C, Seyfert S. 2000. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry.; 68: 89-92.

96. Steinman L. 2000. Despite epitope spreading in the pathogenesis of autoimmune disease, highly restricted approaches to immune therapy may still succeed [with a hedge on this bet]. J Autoimmun.; 14: 278-82.

97. Stinissen P, Raus J, Zhang J. 1997. Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies. Crit Rev Immunol.; 17: 33-75.

98. Stys PK, Ransom BR, Waxman SG, Davis PK. 1990. Role of extracellular calcium in anoxic injury of mammalian central white matter. Proc Natl Acad Sci U S A.; 87: 4212-6.

99. Stys PK, Sontheimer H, Ransom BR, Waxman SG. 1993. Noninactivating, tetrodotoxin-sensitive Na+ conductance in rat optic nerve axons. Proc Natl Acad Sci U S A.; 90: 6976-80.

100. Stys PK, Waxman SG, Ransom BR. 1992. Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+ channels and Na(+)-Ca2+ exchanger. J Neurosci.; 12: 430-9.

101. Taub E, Uswatte G, Pidikiti R. 1999. Constraint-Induced Movement Therapy: a new family of techniques with broad application to physical rehabilitation—a clinical review. J Rehabil Res Dev.; 36: 237-51.

102. Theofilopoulos AN, Balderas RS, Gozes Y, et al. 1985. Association of lpr gene with graft-vs. host disease-like syndrome. J Exp Med.; 162: 1-18.

103. Theofilopoulos AN, Dixon FJ. 1985. Murine models of systemic lupus erythematosus. Adv Immunol.; 37: 269-390.

104. Trapp BD, Ransohoff RM, Fisher E, Rudick RA. 1999. Neurodegeneration in multiple sclerosis: relationship to neurological disability. The Neuroscientist.; 5: 48-57.

105. Tyndall A. 1997. Hematopoietic stem cell transplantation in rheumatic diseases other than systemic sclerosis and systemic lupus erythematosus. J Rheumatol Suppl.; 48.

106. van Bekkum DW. 1993. BMT in experimental autoimmune diseases. Bone Marrow Transplant.; 11: 183-7.

107. Vandenbark AA, Chou YK, Whitham R, et al. 1996. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat Med.; 2: 1109-15.

108. Venters HD, Tang Q, Liu Q, VanHoy RW, Dantzer R, Kelley KW. 1999. A new mechanism of neurodegeneration: a proinflammatory cytokine inhibits receptor signaling by a survival peptide. Proc Natl Acad Sci U S A.; 96: 9879-84.

109. Vialettes B, Maraninchi D, San Marco MP, et al. 1993. Autoimmune polyendocrine failure—type 1 (insulin-dependent) diabetes mellitus and hypothyroidism—after allogeneic bone marrow transplantation in a patient with lymphoblastic leukaemia. Diabetologia.; 36: 541-546.

110. Villoslada P, Hauser SL, Bartke I, et al. 2000. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J Exp Med.; 191: 1799-806.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement